NovaBay Pharmaceuticals Q2 2023 Earnings Report

NovaBay Pharmaceuticals EPS Results

• Actual EPS: -$1.27
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NovaBay Pharmaceuticals Revenue Results

• Actual Revenue: $4.61 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NovaBay Pharmaceuticals Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: N/A

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.